EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Epidemiology of Huntington’s Disease in Iceland

Saga Briem, Vigdis Stefansdottir, Jon Johannes Jónsson, Olafur Sveinsson, Olafur Sveinsson

European Neurology · 2025

DOI: 10.1159/000546150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Neurology, 2025. Verfasst von Saga Briem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Iceland, Reykjavík, Iceland. Hauptthemen laut MEDLINE: Huntington Disease. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by involuntary movements, psychiatric symptoms and cognitive decline. Its prevalence is highest in individuals of European descent. However, a previous study in 2007 in Iceland showed an unusually low incidence and prevalence. The aim of this study was to investigate the incidence and prevalence of HD in Iceland between 2008 and 2022 as well as age, sex, symptoms, number of cytidine-adenosine-guanosine (CAG) repeats, treatment, and prognosis.

Methods

A retrospective epidemiological study was conducted with clinical information obtained from medical records of individuals diagnosed with HD 2008–2022. Information was also obtained from the Department of Genetics at University Hospital of Iceland and neurologists managing HD patients.

Results

Among the 22 diagnosed individuals (11 men) identified, the point prevalence on December 31, 2022, was 4.38 per 100,000 inhabitants, with an average annual incidence rate of 0.314 per 100,000 person-years. The average age at symptom onset was 46.3 years. A total of 21 out of 22 individuals had confirmed HD through genetic testing, with an average CAG repeat length of 42.3 (range 40–45). Five individuals died during the study period, with the most common cause of death being aspiration pneumonia. The average age at death was 70.4 years.

Conclusion

The prevalence and incidence of HD in Iceland have increased compared to the 2007 study but remain lower than in other European populations. Results showed a lower number of CAG repeats in the Icelandic HD population, potentially explaining the higher age at symptom onset and death compared to global averages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseHumansIcelandMaleFemaleMiddle AgedAdultAgedRetrospective StudiesIncidencePrevalenceAge of Onset

Stichwörter der Autor:innen

Autosomal dominantHuntington’s diseaseIcelandIncidencePrevalence

Autor:innen und Institutionen

  • Faculty of Medicine, University of Iceland, Reykjavík, Iceland.
  • Department of Genetics and Molecular Medicine, Landspitali University Hospital, Reykjavík, Iceland.
  • Department of Neurology, Landspitali University Hospital, Reykjavík, Iceland.

Zitieren

APA

Briem, S., Stefansdottir, V., Jónsson, J. J., Sveinsson, O., & Sveinsson, O. (2025). The Epidemiology of Huntington’s Disease in Iceland. European Neurology. https://doi.org/10.1159/000546150

Vancouver

Briem S, Stefansdottir V, Jónsson JJ, Sveinsson O, Sveinsson O. The Epidemiology of Huntington’s Disease in Iceland. European Neurology. 2025. doi:10.1159/000546150

BibTeX
@article{Briem2025,
  author = {Briem, Saga and Stefansdottir, Vigdis and Jónsson, Jon Johannes and Sveinsson, Olafur and Sveinsson, Olafur},
  title = {The Epidemiology of Huntington’s Disease in Iceland},
  journal = {European Neurology},
  year = {2025},
  doi = {10.1159/000546150}
}
Kostenlos starten →